Study design
acute agitation, RS, anxiety
This was a 24 week, randomized, controlled open-label study. Patients were randomly assigned to receive low-dose risperidone (2–3.5 mg/day) and sertraline (50–100 mg/day) in the RS group (n = 109 patients) or normal-dose risperidone (4–6 mg/day) monotherapy in the control group (n = 89 patients) (Additional file Recruited participants were allowed to take clonazepam (2–3 mg/d) during the early phase of treatment to treat sleep problems and relieve anxiety symptoms and acute agitation. Past medical history, ECG, and physical examination reports were obtained from all participants or their relatives.